Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | GPR142 | Q7Z601 | 4/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20279044 | 1.00 | DPP4 (0.39) | DPP4DPP8DPP9GPR142SLC6A3 | |
| SCHEMBL7964218 | 1.00 | DPP4 (0.39) | DPP4DPP8DPP9GPR142SLC6A3 | |
| SCHEMBL19214802 | 0.81 | DPP4 (0.36) | DPP4DPP8DPP9GPR142SLC6A3 | |
| SCHEMBL13624897 | 0.81 | DPP4 (0.36) | DPP4DPP8DPP9GPR142SLC6A3 | |
| SCHEMBL16889011 | 0.80 | — | — | |
| SCHEMBL8739022 | 0.78 | DPP4 (0.36) | DPP4DPP8DPP9SLC6A3SYK | |
| SCHEMBL4551356 | 0.78 | DPP4 (0.36) | DPP4DPP8DPP9SLC6A3SYK | |
| SCHEMBL19143537 | 0.77 | DPP4 (0.39) | DPP4DPP8DPP9GPR142SLC6A3 | |
| SCHEMBL2627123 | 0.77 | DPP4 (0.34) | DPP4DPP8DPP9SLC6A3SYK | |
| Serine SCHEMBL3839203 | 0.76 | DPP4 (0.45) | DPP4DPP8DPP9GPR142SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895571-B2 | Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors | INCYTE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895571-B2 | Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors | INCYTE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895571-B2 | Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors | INCYTE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013056015-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | WO | disclosed |
| US-6274715-B1 | SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | disclosed |
| CN-1244202-A | Tricyclic erythromycin derivatives | ABBOTT LAB (US) | 2000-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | MTOR, PDPK1, PIK3CA | DPP4 2388/4885DPP8 918/4885DPP9 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.